GlassScriptPhysician profile
Osman M Numair
NPI 1073900106
$10,058.73
in general payments reported to CMS, 2019-2025
31 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $585 · 2021: $1,142 · 2022: $1,832 · 2023: $2,301 · 2024: $1,996 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,029 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.23 |
| Education | $206.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,634.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,765.05 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,486.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $704.05 | 2020-2025 | Dupixent |
| Incyte Corporation | $361.43 | 2022-2025 | Opzelura, Iclusig |
| Amgen INC. | $356.65 | 2022-2025 | Actimmune, Tezspire |
| Novartis Pharmaceuticals Corporation | $352.91 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $231.29 | 2020-2024 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $207.51 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $196.42 | 2021-2022 | |
| Pfizer INC. | $193.13 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $192.06 | 2022-2023 | Orladeyo |
| Horizon Therapeutics Plc | $163.80 | 2021-2023 | Actimmune |
| Csl Behring | $152.73 | 2020-2025 | Hizentra |
| Grifols USA, LLC | $143.52 | 2023-2025 | Xembify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $133.68 | 2021-2024 | Cutaquig |
| Seagen INC. | $124.99 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $109.57 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.65 | 2021-2023 | |
| Blueprint Medicines Corporation | $73.82 | 2023-2025 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $68.03 | 2020 | |
| Dermavant Sciences, INC. | $63.77 | 2023-2024 | Vtama |
| Covis Pharma Gmbh | $61.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $45.88 | 2020-2021 | |
| Optinose US, INC. | $31.37 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $24.99 | 2022 | |
| Organon LLC | $21.40 | 2025 | Vtama |
| Leo Pharma INC. | $18.03 | 2025 | Anzupgo |
| Hospira, INC. | $17.19 | 2022 | |
| Kaleo, INC. | $16.48 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Numair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.